2.Research advances in add-on treatment for negative symptoms and cognitive dysfunction in schizophrenia.
Ranran LI ; Gangrui HEI ; Ye YANG ; Renrong WU ; Jingping ZHAO
Journal of Central South University(Medical Sciences) 2020;45(12):1457-1463
Antipsychotic medication is the primary treatment for schizophrenia, which is effective on ameliorating positive symptoms and can reduce the risk of recurrence, but it has limited efficacy for negative symptoms and cognitive dysfunction. The negative symptoms and cognitive dysfunction seriously affects the life quality and social function for the patients with schizophrenia. Currently, there is plenty evidence that antipsychotic drugs combined with adjuvant therapy drugs can effectively improve the negative symptoms and cognitive dysfunction. These drugs include anti-oxidants, nicotinic acetylcholine receptors and neuro-inflammatory drugs (anti-inflammatory drugs, minocycline), which show potential clinical effects.
Anti-Inflammatory Agents/therapeutic use*
;
Antipsychotic Agents/therapeutic use*
;
Cognitive Dysfunction/etiology*
;
Humans
;
Minocycline/therapeutic use*
;
Schizophrenia/drug therapy*
3.Efficacy of infliximab in treatment on inflammatory bowel disease and factors affecting the therapeutic effect.
Journal of Southern Medical University 2013;33(12):1833-1838
Infliximab has shown its superiority and safety in the treatment of inflammatory bowel disease (IBD) that failed to respond to traditional medical therapy, in refractory cases with obvious adverse reactions, and in "top-down therapy". For standardized and effective management of IBD, experts worldwide have consecutively issued the 2010 European ECCO guide, 2011 London consensus, and 2012 Chinese consensus. In this paper, based on the latest expert consensus worldwide, we reviewed the efficacy of infliximab treatment on IBD and the factors affecting its therapeutic effect.
Anti-Inflammatory Agents, Non-Steroidal
;
therapeutic use
;
Antibodies, Monoclonal
;
therapeutic use
;
Gastrointestinal Agents
;
therapeutic use
;
Humans
;
Inflammatory Bowel Diseases
;
drug therapy
;
Infliximab
5.Research advances of Tasmayi.
China Journal of Chinese Materia Medica 2013;38(3):443-448
Tasmayi (mumie, shilajit) is a pale brown to black substance which leaks from the layers of rocks in many mountain ranges during the warm summer months. In traditional Kazakh medicine, it is used for the treatment of bone fracture and many inflammatory ailments. It is also used as a remedy in the traditional medical systems of many countries such as India, Russia and Kazakhstan. According to the literatures, Tasmayi possesses anti-inflammatory, antiulcerogenic, antibacterial, free radical scavenging, antioxidative, memory enhancing, antidiabetic, antistress, antiallergic, immunomodulative, anti AIDS, anabolic and regeneration stimulating activities. The major physiological action of Tasmayi could be belonging to the presence of dibenzo-alpha-pyrones along with humic and fulvic acids.
Animals
;
Anti-Bacterial Agents
;
therapeutic use
;
Anti-Inflammatory Agents
;
therapeutic use
;
Biomedical Research
;
methods
;
trends
;
Free Radical Scavengers
;
therapeutic use
;
Humans
;
Hypoglycemic Agents
;
therapeutic use
;
India
;
Kazakhstan
;
Medicine, Traditional
;
methods
;
trends
;
Minerals
;
therapeutic use
;
Resins, Plant
;
therapeutic use
;
Russia
6.Herbal medicine in the treatment of patients with type 2 diabetes mellitus.
Guo-Ming PANG ; Fang-Xu LI ; Yong YAN ; Yin ZHANG ; Li-Li KONG ; Pu ZHU ; Kai-Feng WANG ; Fang ZHANG ; Bin LIU ; Cheng LU
Chinese Medical Journal 2019;132(1):78-85
7.Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS.
Wen-Long WEI ; Shi-Fei WU ; Hao-Jv LI ; Zhen-Wei LI ; Hua QU ; Chang-Liang YAO ; Jian-Qing ZHANG ; Jia-Yuan LI ; Wan-Ying WU ; De-An GUO
Chinese Journal of Natural Medicines (English Ed.) 2021;19(6):473-480
Huashi Baidu prescription (HSBDF), recommended in the Guideline for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Pneumonia (On Trials, the Seventh Edition), was clinically used to treat severe corona virus disease 2019 (COVID-19) with cough, blood-stained sputum, inhibited defecation, red tongue etc. symptoms. This study was aimed to elucidate and profile the knowledge on its chemical constituents and the potential anti-inflammatory effect in vitro. In the study, the chemical constituents in extract of HSBDF were characterized by UPLC-Q-TOF/MS in both negative and positive modes, and the pro-inflammatory cytokines were measured by enzyme-linked immunosorbent assays (ELISA) to determine the effects of HSBDF in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. The results showed that a total of 217 chemical constituents were tentativedly characterized in HSBDF. Moreover, HSBDF could alleviate the expression levels of IL-6 and TNF-α in the cell models, indicating that the antiviral effects of HSBDF might be associated with regulation of the inflammatory cytokines production in RAW264.7 cells. We hope that the results could be served as the basic data for further study of HSBDF on anti-COVID-19 effect.
Anti-Inflammatory Agents/therapeutic use*
;
Antiviral Agents/therapeutic use*
;
COVID-19/drug therapy*
;
Drugs, Chinese Herbal/therapeutic use*
;
Humans
;
Plant Extracts/therapeutic use*
;
SARS-CoV-2/drug effects*
8.To intensify our understanding about management of severe burn infection.
Chinese Journal of Burns 2009;25(2):81-83
Nowadays, it is necessary to emphasize the three basic inseparable elements in the treatment of severe burn infection, which are systemic care, burn wound care, and rational use of antimicrobials topically or systematically. Systemic care has been shifted from simple nutritional support to maintaining the systemic homeostasis, including balancing immune-inflammatory response, and protecting organs from dysfunction. Some work focused on regulating systemic immune response in the initial phase and the balance of inflammatory response after occurrence of severe burn infection have been reported. These results at least broaden our thinking to recognize that treatment should not only destroy microbes, but also balance the response of the body. Escharectomy in earlier phase has been a consensus. Currently, we turn our vision into how to use "damage control surgery (DCS)" concept in management of severe burn. DCS in burn care includes the evaluation of perioperative situation more accurate to make a more appropriate surgical decision. Meanwhile, an overall strategy should be established to confront the rapidly increasing drug resistance of the pathogens. The release of endotoxin after use of antimicrobials, which has been studied widely, should be explored further.
Anti-Infective Agents
;
therapeutic use
;
Burns
;
complications
;
therapy
;
Humans
;
Infection Control
;
Systemic Inflammatory Response Syndrome
;
therapy
9.Recent development of non-steroidal anti-inflammatory drugs on the neuro-inflammation of Alzheimer's disease.
Xiao-Wei MA ; Jin-Ze LI ; Tian-Tai ZHANG ; Guan-Hua DU
Acta Pharmaceutica Sinica 2014;49(9):1211-1217
Neuropathological, clinical epidemiology and animal models studies provide clear evidence for the activation of neuroinflammation in Alzheimer's disease (AD), and long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is linked with reduced risk to develop the disease. But the clinical trials got a negative outcome with traditional NSAIDs treating AD. The therapeutic effects of NSAIDs on Alzheimer's disease are still not clear based on the present research. Profound study for anti-inflammatory mechanisms and standardized clinical trials are needed. As cause and effect relationships between neuroinflammation and AD are being worked out, the challenge is how to realize the effect of traditional NSAIDs on treating AD.
Alzheimer Disease
;
drug therapy
;
Animals
;
Anti-Inflammatory Agents, Non-Steroidal
;
therapeutic use
;
Humans
;
Inflammation
;
drug therapy